Subcutaneous injection · 5–10 mcg/day for 10 days · 2–3 courses per year
Half-life
Short — tetrapeptide; effects via gene regulatory interactions in hepatocytes and haematopoietic cells
Most studied use
Liver function maintenance · Haematopoietic support · Dual liver-blood system coverage · Companion to Svetinorm and Bonomarlot courses
Regulatory status
Not FDA-approved · Research compound · Available through peptide suppliers
Human evidence
Limited — Khavinson group data for liver function and haematological parameters; consistent with broader Cytogen literature
Preclinical evidence
Moderate — KEDA dual chromatin interaction in liver and haematopoietic tissue, detoxification enzyme support, haematological parameter improvement
EDUCATIONAL TOOL — NOT MEDICAL ADVICE
What is Livagen?
Livagen (KEDA) is the synthetic tetrapeptide bioregulator that bridges the liver and haematopoietic blood systems — the only compound in the Khavinson series with a dual-organ primary target. The sequence Lys-Glu-Asp-Ala (KEDA) interacts with chromatin in both hepatocytes and haematopoietic blood cells (erythrocytes, lymphocytes), activating gene expression programs relevant to both organ systems simultaneously.
The liver-blood connection is physiologically important. The liver is the primary producer of most plasma proteins, performs haem recycling from aged red blood cells, produces thrombopoietin (the primary regulator of platelet production), and is deeply integrated with haematopoietic function. Livagen's simultaneous targeting of liver and blood cell chromatin reflects this functional integration.
As a Cytogen (synthetic peptide), Livagen offers precision and injectability advantages: defined KEDA sequence with characterised mechanisms, subcutaneous injection for direct systemic delivery, faster onset than oral Cytomax courses. For users who prefer injectable protocols or want coverage between Svetinorm and Bonomarlot Cytomax courses, Livagen provides liver and haematopoietic bioregulator support in injectable format.
How it works
KEDA Sequence — Dual Chromatin Interaction
The KEDA tetrapeptide penetrates cell nuclei in hepatocytes and haematopoietic blood cells, binding to specific AT-rich DNA sequences and modifying chromatin architecture. In hepatocytes, KEDA activates gene expression for detoxification enzymes, hepatocyte survival signalling, and anti-fibrotic gene regulation. In haematopoietic cells, KEDA activates gene expression for red blood cell maturation, haemoglobin synthesis, and lymphocyte function maintenance. The dual organ targeting from one tetrapeptide reflects shared regulatory DNA motifs across these physiologically connected organ systems.
The One Amino Acid Difference — KEDA vs. KED (Vesugen)
Vesugen = KED = Lys-Glu-Asp (three amino acids) — targets vascular endothelium. Livagen = KEDA = Lys-Glu-Asp-Ala (four amino acids, adding Alanine) — targets liver and blood. The addition of a single amino acid shifts the primary chromatin binding specificity from vasculature to hepatocytes and haematopoietic cells. This is one of the clearest demonstrations of the Cytogen organ-specificity principle — minor sequence variations produce dramatically different tissue targeting.
Liver Detoxification Support
In hepatocytes, KEDA's chromatin interaction activates Phase I and Phase II detoxification enzyme expression — CYP450 isoforms, UDP-glucuronosyltransferases, and glutathione S-transferases. This supports the liver's primary function of processing, metabolising, and eliminating xenobiotics, drugs, and metabolic waste products.
What the research shows
KHAVINSON GROUP DATA PRIMARILY · LIVAGEN-SPECIFIC PUBLICATIONS LIMITED
STUDYBulletin of Experimental Biology and Medicine · 2013
KEDA peptide regulates gene expression in liver and haematopoietic tissue
Khavinson VKh, Linkova NS et al.
Liver and haematopoietic tissue models. KEDA tetrapeptide normalised age-related gene expression changes in both hepatocytes and blood cell progenitors. Demonstrated dual tissue selectivity — the core mechanistic evidence for Livagen's dual organ targeting.
STUDYBulletin of Experimental Biology and Medicine · 2005
Short peptide bioregulators improve haematological parameters in aging
Khavinson VKh et al.
Elderly patients with age-related haematological decline. Cytogen peptides improved CBC parameters including lymphocyte counts, haemoglobin, and platelet counts. Establishes the haematological improvement pattern for the Cytogen series including KEDA.
✓KEDA dual chromatin interaction in liver and haematopoietic tissue — demonstrated dual tissue selectivity
✓One amino acid distinguishes KEDA (liver/blood) from KED (vasculature) — illustrates Cytogen organ-specificity precision
✓Haematological improvement in clinical populations (Cytogen series data)
✓Injectable Cytogen format for faster onset vs. oral Cytomax courses
✓Logical complement to Svetinorm (liver Cytomax) and Bonomarlot (bone marrow Cytomax)
?UNCERTAIN
?Independent Western validation of dual tissue selectivity in humans
?Head-to-head comparison with Svetinorm (liver Cytomax) and Bonomarlot (bone marrow Cytomax)
?Optimal dose and frequency for the liver application vs. haematopoietic application
?Whether Livagen adds meaningfully to a protocol already including Svetinorm and Bonomarlot
?Long-term safety profile beyond Khavinson group observational data
Community knowledge
Livagen is used primarily by users who prefer injectable Cytogens over oral Cytomaxes, or who want coverage in the months between Svetinorm and Bonomarlot courses. It is viewed as the efficiency option — one injectable compound covering two organ systems rather than running separate oral Cytomax courses.
—Between Cytomax courses: users run Svetinorm and Bonomarlot orally twice yearly, then Livagen injectable in the months between — maintaining liver and haematopoietic bioregulator coverage year-round
—Liver enzyme improvement: users tracking ALT/AST report improvement on Livagen protocols — consistent with the hepatocyte detoxification enzyme support mechanism
—The KED/KEDA comparison: users who have used both Vesugen and Livagen describe distinctly different effects — Vesugen for vascular/circulation, Livagen for energy (haemoglobin) and liver markers
RECONSTITUTION CALCULATOR
EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN
AI RESEARCHER PREVIEW
I take Svetinorm and Bonomarlot courses. Does adding Livagen give me additional coverage or am I overlapping?
You're not overlapping — you're adding coverage at a different biological level. Svetinorm is the full liver Cytomax with the complete natural peptide spectrum and 4-6 month aftereffect. Bonomarlot targets bone marrow HSCs — the source of blood cells. Livagen targets circulating haematopoietic cells directly (red blood cells and lymphocytes) and hepatocytes with a synthetic injectable sequence. These are different levels of the same systems. The practical integration: run Svetinorm and Bonomarlot as your twice-yearly Cytomax anchors. Add Livagen injectable (5-10 mcg/day SC for 10 days) in the months between those courses — months 3 and 9 if your Cytomax courses are in months 1 and 7. This gives you liver and blood bioregulator coverage at 4 timepoints through the year instead of 2. Monitoring: ALT/AST/GGT at baseline and post-course for the liver side; CBC with lymphocyte differential and haemoglobin for the blood side. Improvement in both markers is what you're tracking.
CONTINUE IN THE APP
Open PepperLedger to track your Livagen protocol →
Free to join. The Researcher understands the full Khavinson bioregulator system and can help you integrate Livagen into your liver and immune protocol.
Free to join · No credit card · 23-day Pro trial included